Neurology
-
Randomized Controlled Trial Multicenter Study
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. ⋯ Class II evidence that 52 weeks of treatment with erenumab 70 and 140 mg subcutaneously monthly results in sustained reductions in monthly migraine days and similar dose tolerability for patients with episodic migraine.